Skip to main content

Table 3 Validation of the serum cytokine array experiment in the initial screening cohort

From: An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes

Cytokine Method PSP/CBS MSA PD Controls p-value
ICAM-1 Array 0.98 ± 0.25 0.47 ± 0.09 0.62 ± 0.15 1.00 ± 0.28 <0.05a
(ICAM1) FCM 1.25 ± 0.85 0.75 ± 0.29 0.86 ± 0.43 1.00 ± 0.73 nsb
IL-2 Ra Array 2.14 ± 0.47 1.87 ± 0.10 1.24 ± 0.06 1.00 ± 0.14 <0.05a
(IL2RA) ELISA 1.44 ± 0.76 1.24 ± 0.61 1.15 ± 0.55 1.00 ± 0.29 nsb
Leptin Array 1.93 ± 0.11 1.13 ± 0.23 1.91 ± 0.46 1.00 ± 0.11 <0.05a
(LEP) FCM 2.95 ± 4.89 1.42 ± 1.15 1.86 ± 1.88 1.00 ± 0.89 nsb
MCP-4 Array 7.18 ± 0.85 2.16 ± 1.39 1.71 ± 0.80 1.00 ± 0.76 <0.05a
(CCL13) ELISA 1.15 ± 0.32 0.91 ± 0.37 1.02 ± 0.32 1.00 ± 0.42 nsb
PDGF-BB Array 1.87 ± 0.50 1.34 ± 0.18 1.34 ± 0.22 1.00 ± 0.44 <0.05a
(PDGFB) FCM 1.42 ± 0.30 1.32 ± 0.39 1.11 ± 0.28 1.00 ± 0.33 <0.05b
Prolactin Array 4.17 ± 1.74 1.03 ± 0.15 0.99 ± 0.08 1.00 ± 0.19 <0.05a
(PRL) ELISA 3.06 ± 4.15 1.39 ± 1.34 0.71 ± 1.12 1.00 ± 0.50 <0.05b
RANTES Array 1.46 ± 0.29 1.32 ± 0.11 1.20 ± 0.25 1.00 ± 0.20 <0.05a
(CCL5) ELISA 1.13 ± 0.59 0.83 ±0.49 0.94 ± 0.32 1.00 ± 0.51 nsb
  1. Cytokine microarray data were validated by ELISA (MCP-4, prolactin, RANTES and IL-2RA) or by Flow-Cytomix assays (ICAM-1, Leptin and PDGF-BB) in individual samples. All data are shown as means with standard deviations of the ratio to the mean of the control group. Array = Raybiotech cytokine microarray, FCM = Flow-Cytomix, ELISA = enzyme-linked immunosorbent assay, ns = statistically non significant.
  2. P-value: groups were compared using a SAM analysis and b Kruskal-Wallis test.